Skip to content

Calculus VCT 0% Initial Fee – Limited Time Offer

Calculus Capital is to waive initial fees on its new VCT until the end of the year, making it one of the most attractive in the current marketplace. Click here to download the Calculus VCT Brochure Most providers charge “promoter fees” of between 3% and 5% and Calculus will waive this fee if a subscription … Continued

Synpromics named among the Top 50 fastest growing technology companies in the UK

Calculus Capital portfolio company, Synpromics the leader in gene control, has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night. The Deloitte Technology Fast 50 is one of the UK’s foremost technology award programmes. It is a ranking of the country’s 50 fastest growing technology companies, based … Continued

Calculus Capital wins Best EIS Investment Manager at the Growth Investor Awards 2018

Calculus Capital has come out on top in the intense race for the Best EIS Investment Manager award at the fourth annual Growth Investor Awards, organised by Intelligent Partnership. Calculus was also named Best EIS Investment Manager in the 2016 awards. Calculus Capital impressed the judging panel with its deep long-term commitment to EIS through both … Continued

Benito’s Hat announces two new sites

Mexican restaurant Benito’s Hat has announced two brand new branches in St Albans and The O2 Arena, opening in December and early 2019 respectively. The news comes following an investment of £1 million to fund a three year growth plan in London and throughout the UK. Managing Director of Benito’s Hat, Michael Pearson said: “We … Continued

Spotlight On: Synpromics

As part of our ‘Spotlight On’ series, we focus on Synpromics, a Scottish-based synthetic biology company applying gene therapy treatments to develop cures for genetic diseases Our short video features Synpromics CEO David Venables; Founder and Chief Scientific Officer, Michael Roberts and Calculus Capital Investment Director, Alexander Crawford. Synpromics, an Edinburgh-based synthetic biology company, is developing a strategic … Continued

Arecor successfully defends key European Patent

Arecor successfully defends a key European Patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage. Arecor Ltd, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology … Continued